Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
43 studies found for:    " February 04, 2009":" March 06, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
2 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption
3 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: HIV;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
4 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
5 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
6 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
7 Completed Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
8 Unknown  A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Conditions: HIV-1;   HIV Infections
Interventions: Other: VircoType HIV-1 genotypic interpretation;   Other: Local Expert Review of HIV Genotypic resistance testing
9 Completed
Has Results
Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Interactive injection and sexual risk intervention;   Behavioral: Interactive Sexual Risk Intervention;   Behavioral: Interactive Injection Risk Intervention
10 Completed Safety of Acidform Lubricant in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Acidform Lubricant;   Drug: HEC gel
11 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
12 Completed
Has Results
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Other: Placebo;   Biological: TUTI-16 (0.03mg);   Biological: TUTI-16 (0.1mg);   Biological: TUTI-16 (0.6mg)
13 Completed ID and Testing Via Friendship Networks
Conditions: Asymptomatic HIV;   HIV Infections
Interventions: Other: Index Recruiter;   Other: Friendship Network Member
14 Completed Intensive Viral Dynamics Substudy of A5248
Conditions: HIV Infections;   Treatment Naive
Intervention:
15 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
Intervention:
16 Completed
Has Results
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
Condition: HIV Infection
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Ritonavir;   Drug: Atazanavir;   Drug: Raltegravir;   Drug: Darunavir
17 Completed
Has Results
Exercise, Oxidative Stress and HIV
Condition: HIV Infections
Intervention:
18 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
19 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: Etravirine;   Drug: Rilpivirine;   Drug: Darunavir/Cobicistat (FDC)
20 Completed
Has Results
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Conditions: Herpes Zoster;   HIV Infections
Interventions: Biological: ZOSTAVAX;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.